Goldman Sachs Group Inc. raised its position in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 3.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 551,921 shares of the medical equipment provider’s stock after acquiring an additional 18,750 shares during the period. Goldman Sachs Group Inc. owned approximately 1.26% of ABIOMED worth $79,090,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Employees Retirement System of Texas acquired a new position in ABIOMED in the second quarter worth about $1,720,000. Balyasny Asset Management LLC acquired a new stake in shares of ABIOMED in the second quarter valued at approximately $607,000. Zacks Investment Management acquired a new stake in shares of ABIOMED in the second quarter valued at approximately $2,250,000. OxFORD Asset Management LLP acquired a new stake in shares of ABIOMED in the second quarter valued at approximately $782,000. Finally, Dimensional Fund Advisors LP increased its holdings in shares of ABIOMED by 2.8% in the second quarter. Dimensional Fund Advisors LP now owns 141,970 shares of the medical equipment provider’s stock valued at $20,343,000 after purchasing an additional 3,830 shares in the last quarter. Institutional investors own 89.69% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “ABIOMED, Inc. (ABMD) Holdings Raised by Goldman Sachs Group Inc.” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/10/05/abiomed-inc-abmd-holdings-raised-by-goldman-sachs-group-inc.html.

In other news, Director Eric A. Md Rose sold 23,018 shares of ABIOMED stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of $151.09, for a total value of $3,477,789.62. Following the completion of the transaction, the director now owns 24,652 shares in the company, valued at $3,724,670.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Andrew J. Greenfield sold 11,282 shares of ABIOMED stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $169.32, for a total transaction of $1,910,268.24. The disclosure for this sale can be found here. Insiders have sold 61,782 shares of company stock valued at $9,513,610 in the last 90 days. 7.00% of the stock is currently owned by corporate insiders.

Shares of ABIOMED, Inc. (ABMD) opened at 172.31 on Thursday. The company has a 50-day moving average of $156.80 and a 200 day moving average of $142.06. ABIOMED, Inc. has a 52-week low of $95.14 and a 52-week high of $172.31. The company has a market capitalization of $7.60 billion, a PE ratio of 100.77 and a beta of 0.27.

ABIOMED (NASDAQ:ABMD) last released its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.03. The firm had revenue of $132.47 million for the quarter, compared to analyst estimates of $130.83 million. ABIOMED had a net margin of 16.13% and a return on equity of 13.03%. The business’s quarterly revenue was up 28.6% compared to the same quarter last year. During the same period last year, the firm earned $0.29 earnings per share. Analysts predict that ABIOMED, Inc. will post $2.24 earnings per share for the current year.

A number of equities analysts have issued reports on ABMD shares. BidaskClub cut shares of ABIOMED from a “buy” rating to a “hold” rating in a research note on Tuesday, July 25th. Piper Jaffray Companies reissued an “overweight” rating and set a $160.00 price target (up from $145.00) on shares of ABIOMED in a research report on Thursday, July 27th. Zacks Investment Research cut shares of ABIOMED from a “buy” rating to a “hold” rating in a research report on Monday, August 7th. Jefferies Group LLC lifted their price target on shares of ABIOMED from $165.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday, August 4th. Finally, SunTrust Banks, Inc. assumed coverage on shares of ABIOMED in a research report on Friday, September 29th. They set a “buy” rating and a $195.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $167.00.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Stock Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related stocks with our FREE daily email newsletter.